Immunome's $4.39 Million Insider Sale: A Pre-Planned Exit Amidst Robust Pipeline Momentum

Related Articles

Block's Insider Sales: A Pre-Planned Exit Amidst Strong Fundamentals

1 months ago

CoreWeave's $17.7 Million Insider Sale: Pre-Planned Diversification in a Discounted AI Powerhouse

3 weeks ago

OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

2 months ago

Procore's Insider Sales: A Planned Exit, Not a Crisis, Amidst Valuation Reset

1 months ago

Category

You may also like

Stock News•9 hours ago

Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results

Prenetics' CEO and CFO bought $1.0 million of shares in the open market between Aug. 20-25, 2026, after Q2 results. Leadership's cumulative personal investment since Nov.

PRE

Share

Stock News•1 week ago

Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript

Innate Pharma discussed a EUR 30 million equity raise, a strategic partnership, and pipeline advancement. The capital injection could fund development programs and extend its cash runway, though terms...

IPHA

Share

Stock News•1 months ago

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

ImmunityBio's ANKTIVA is driving rapid revenue growth and market share in NMIBC. A 40% pullback from 52-week highs creates an attractive entry, supported by a strong balance sheet and robust pipeline.

IBRX

Share

Stock News•1 months ago

What This Immunome Sale Means a Day Before a Big FDA Milestone

An Immunome insider sold 100K shares (~$2.4M) on July 6-7, 2026, representing 32% of their holdings, ahead of a major FDA milestone.

IMNM

Share